InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.
Read More…
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
Phone+1-857-4536553
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees43
Next Earnings Date11/5/2019 (Estimated)
OptionableNot Optionable
InspireMD (NYSEAMERICAN:NSPR) Frequently Asked Questions
What is InspireMD's stock symbol?
InspireMD trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NSPR."
When did InspireMD's stock split? How did InspireMD's stock split work?
InspireMD shares reverse split before market open on Monday, April 1st 2019. The 1-50 reverse split was announced on Tuesday, March 26th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 29th 2019. An investor that had 100 shares of InspireMD stock prior to the reverse split would have 2 shares after the split.
How were InspireMD's earnings last quarter?
InspireMD Inc (NYSEAMERICAN:NSPR) announced its quarterly earnings data on Tuesday, August, 6th. The medical equipment provider reported ($1.59) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($2.00) by $0.41. The medical equipment provider earned $1.35 million during the quarter, compared to analyst estimates of $1.30 million. View InspireMD's Earnings History.
When is InspireMD's next earnings date?
What price target have analysts set for NSPR?
1 brokerages have issued 12 month price targets for InspireMD's stock. Their forecasts range from $5.00 to $5.00. On average, they expect InspireMD's stock price to reach $5.00 in the next year. This suggests a possible upside of 334.8% from the stock's current price. View Analyst Price Targets for InspireMD.
What is the consensus analysts' recommendation for InspireMD?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InspireMD in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InspireMD.
What are Wall Street analysts saying about InspireMD stock?
Here are some recent quotes from research analysts about InspireMD stock:
- 1. According to Zacks Investment Research, "InspireMD Inc. is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. It focuses on applying its technology to develop additional products used for other vascular procedures, specifically carotid and peripheral procedures. InspireMD Inc. is headquartered in Tel Aviv, Israel. " (10/11/2019)
- 2. HC Wainwright analysts commented, "Our $5 PT was derived by using a 25% weighted-average cost of capital to discount free cash flows we project 2019-2030, and dividing them by our projected number of shares for each year to account for the effects of share dilution, and then ascribing a 1% terminal growth rate and 75% probability of." (8/19/2019)
Has InspireMD been receiving favorable news coverage?
Media coverage about NSPR stock has trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. InspireMD earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for InspireMD.
Are investors shorting InspireMD?
InspireMD saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 152,000 shares, an increase of 14.4% from the August 15th total of 132,900 shares. Based on an average daily volume of 191,900 shares, the days-to-cover ratio is currently 0.8 days. Currently, 11.7% of the company's stock are short sold. View InspireMD's Current Options Chain.
Who are some of InspireMD's key competitors?
What other stocks do shareholders of InspireMD own?
Who are InspireMD's key executives?
InspireMD's management team includes the folowing people:
- Dr. James J. Barry, Pres, CEO & Director (Age 60)
- Mr. Craig Shore, CFO, Chief Admin. Officer, Sec. & Treasurer (Age 58)
- Mr. Agustin V. Gago, Exec. VP & Chief Commercial Officer (Age 59)
- Mr. Roei Samuri, VP of Operations
- Dr. Sol J. Barer, Special Advisor to the Board (Age 72)
How do I buy shares of InspireMD?
Shares of NSPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is InspireMD's stock price today?
One share of NSPR stock can currently be purchased for approximately $1.15.
How big of a company is InspireMD?
What is InspireMD's official website?
How can I contact InspireMD?
InspireMD's mailing address is 4 Menorat Hamaor St., TEL AVIV-YAFO, MA 6744832, Israel. The medical equipment provider can be reached via phone at +1-857-4536553.
MarketBeat Community Rating for InspireMD (NYSEAMERICAN NSPR)
MarketBeat's community ratings are surveys of what our community members think about InspireMD and other stocks. Vote "Outperform" if you believe NSPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
